

2015 MDACC Hematology Oncology Board Review Course: Melanoma

References

- 1 Akbani R, Akdemir Kadir C, Aksoy BA, Albert M, Ally A, Amin Samirkumar B *et al.* Genomic Classification of Cutaneous Melanoma. *Cell* 2015; 161: 1681-1696.
- 2 Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K *et al.* High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. *J Clin Oncol* 1999; 17: 2105-.
- 3 Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. *Cancer J Sci Am* 2000; 6 Suppl 1: S11-14.
- 4 Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR *et al.* Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* 2009; 27: 6199-6206.
- 5 Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. *Biochem Pharmacol* 2014; 87: 381-389.
- 6 Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J *et al.* Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med* 2011; 364: 2507-2516.
- 7 Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P *et al.* BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. *Cancer Discov* 2012; 2: 791-797.
- 8 Davar D, Tarhini AA, Kirkwood JM. Adjuvant Therapy for Melanoma. *The Cancer Journal* 2012; 18: 192-202 110.1097/PPO.1090b1013e31824f31118b.
- 9 Davies MA. Targeted therapy for cutaneous melanoma: beyond BRAF. *J Patient-Centered Res Rev* 2014; 1: 12-20.
- 10 Davies MA. Role and complexity of next-generation sequencing in melanoma. *Cancer Cytopathology* 2015: n/a-n/a.
- 11 Dummer R, Daud A, Puzanov I, Hamid O, Schadendorf D, Robert C *et al.* A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. *Journal of translational medicine* 2015; 13: 2062.

- 12 Eggermont AM, Suci S, Testori A, Santinami M, Kruit WH, Marsden J *et al.* Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. *J Clin Oncol* 2012; 30: 3810-3818.
- 13 Eggermont AMM, Suci S, Santinami M, Testori A, Kruit WHJ, Marsden J *et al.* Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. *The Lancet* 2008; 372: 117-126.
- 14 Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA *et al.* Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* 2010; 363: 809-819.
- 15 Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J *et al.* Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. *New England Journal of Medicine* 2012.
- 16 Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M *et al.* Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. *New England Journal of Medicine* 2012; 367: 107-114.
- 17 Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT *et al.* Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma-An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. *J Clin Oncol* 2014; 32: 3771-3778.
- 18 Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects. *The Oncologist* 2011; 16: 5-24.
- 19 Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R *et al.* RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature* 2010; 464: 431-435.
- 20 Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M *et al.* Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2012; 380: 358-365.
- 21 Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM *et al.* Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. *Lancet Oncol* 2015.
- 22 Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A *et al.* Major response to imatinib mesylate in KIT-mutated melanoma. *J Clin Oncol* 2008; 26: 2046-2051.

- 23 Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB *et al.* Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. *N Engl J Med* 2010; 363: 711-723.
- 24 Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A *et al.* Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. *J Clin Oncol* 2013; 31: 3182-3190.
- 25 Kefford RF, Arkenau H, Brown MP, Milward M, Infante JR, Long GV *et al.* Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. *J Clin Oncol* 2010; 28: 8503.
- 26 Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma. *Clinical Cancer Research* 2004; 10: 1670-1677.
- 27 Larkin J, Ascierto PA, Dréno B, Atkinson V, Liskay G, Maio M *et al.* Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. *New England Journal of Medicine* 2014; 371: 1867-1876.
- 28 Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD *et al.* Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *New England Journal of Medicine* 2015; 373: 23-34.
- 29 Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A *et al.* Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 2013; 499: 214-218.
- 30 Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB *et al.* Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. *The Lancet Oncology* 2012.
- 31 Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J *et al.* Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. *New England Journal of Medicine* 2014; 371: 1877-1888.
- 32 Robert C, Thomas L, Bondarenko I, O'Day S, M.D. JW, Garbe C *et al.* Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. *New England Journal of Medicine* 2011; 364: 2517-2526.

- 33 Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S, investigators MDX. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. *Clin Cancer Res* 2013; 19: 2232-2239.
- 34 Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R *et al.* Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet* 2014; 384: 1109-1117.
- 35 Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D *et al.* Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. *New England Journal of Medicine* 2015; 372: 30-39.
- 36 Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L *et al.* Nivolumab in Previously Untreated Melanoma without BRAF Mutation. *New England Journal of Medicine* 2015; 372: 320-330.
- 37 Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L *et al.* Pembrolizumab versus Ipilimumab in Advanced Melanoma. *New England Journal of Medicine* 2015; 0: null.
- 38 Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O *et al.* Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *Journal of Clinical Oncology* 2015.
- 39 Woodman SE, Davies MA. Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics. *Biochemical Pharmacology* 2010; 80: 568-574.
- 40 Woodman SE, Lazar AJ, Aldape KD, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. *Clin Cancer Res* 2012; 18: 1195-2000.